文献速递泌尿男性生殖肿瘤

新辅助Sacituzumab Govitecan治疗肌层浸润性膀胱癌:SURE-01试验主要结果

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.
PubMed 文献 · J Clin Oncol · 2026-05-31

SURE-01 II期试验评估新辅助Sacituzumab Govitecan(SG)后行根治性膀胱切除术(RC)在不适/拒绝新辅助化疗的肌层浸润性膀胱癌(MIBC)患者中的疗效。44例可评估患者接受SG(起始10 mg/kg,后因两例死亡调整为7.5 mg/kg并预防性使用粒细胞集落刺激因子)治疗,主要终点病理完全缓解(pT0N0)率为9.1%,但总体ypT0N0-x率为29.5%,非管腔亚型中ypT0反应富集(46% vs 管腔型14%),24个月无事件生存率为71.4%,安全性可控。

要点

  • 新辅助SG在不适/拒绝NAC的MIBC中显示活性,调整后剂量7.5 mg/kg安全性可控。
  • 方案定义的ypT0N0率为9.1%,但总体ypT0N0-x率达29.5%,非管腔亚型反应更优。
  • 24个月EFS率为71.4%,TOP1低表达者EFS更长,支持TROP2作为MIBC治疗靶点。

核心结论

  • 新辅助SG在调整剂量7.5 mg/kg后具有活性且安全性可控,证实TROP2是MIBC的合适靶点。

研究设计与样本

  • II期SURE-01试验(NCT05226117)纳入44例cT2-T4aN0M0、不适/拒绝NAC的MIBC患者,接受4周期SG后行RC。
  • SG初始剂量10 mg/kg(第1、8天,每3周),因两例死亡(一例治疗相关)方案修改为7.5 mg/kg并预防性使用粒细胞集落刺激因子。
  • 主要终点为病理完全缓解(pT0N0)率,并对基线肿瘤样本进行转录组和基因组分析。

主要发现

  • 意向治疗人群中,方案定义的ypT0N0率为9.1%(95%CI 2.5-21.7),总体ypT0N0-x率为29.5%(95%CI 16.7-45.2)。
  • 非管腔亚型ypT0反应富集:46% vs 管腔型14%。
  • 24个月无事件生存(EFS)率为71.4%(95%CI 58-87.8),TOP1低表达者EFS更长。
  • 调整剂量后3-4级治疗相关不良事件发生率为13.9%(5例)。
  • 中位随访22个月(IQR 15-26);26例(59.1%)为cT3-4期,20例(45.5%)为变异组织学,14例(31.8%)拒绝RC。

关键数值与推荐

  • 病理完全缓解定义为ypT0N0;总体ypT0N0-x包括拒绝RC但重复TURBT或主动监测者。

临床怎么用

  • 对于不适/拒绝NAC的MIBC患者,新辅助SG(7.5 mg/kg联合预防性粒细胞集落刺激因子)可作为潜在选择,尤其非管腔亚型可能获益更多。

局限性

  • 样本量小(44例),且方案因早期死亡事件中途调整剂量。
  • 14例(31.8%)患者拒绝RC,可能影响病理终点的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate neoadjuvant sacituzumab govitecan (SG), followed by radical cystectomy (RC), in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for/refuse neoadjuvant chemotherapy (NAC). We report the results of the primary analysis and biomarker analyses of the phase II SURE-01 trial (ClinicalTrials.gov identifier: NCT05226117). PATIENTS AND METHODS: Patients were age 18 years and older, had Eastern Cooperative Oncology Group performance status 0-1, had histologically confirmed cT2-T4aN0M0 MIBC, were ineligible/refusing NAC, and were scheduled for RC received four cycles of SG 10 mg/kg on day 1 and day 8, once every 3 weeks, followed by RC. The primary outcome measure was the pathologic complete response (pT0N0) rate. Transcriptome-wide analyses and comprehensive genomic profiling assays were performed on baseline tumor samples. RESULTS: From March 2022 to July 2025, 44 patients were treated and efficacy evaluable. After the initial eight patients enrolled, the protocol was amended with a SG dose of 7.5 mg/kg, with primary prophylaxis for neutropenia, due to the occurrence of two deaths (one treatment-related). Subsequent grade 3-4 treatment-related adverse-events occurred in 5 patients (13.9%). Twenty-six patients (59.1%) had a cT3-4 stage and 20 (45.5%) had a variant histology. Fourteen patients (31.8%) refused to undergo RC, accounting for 12 repeating a transurethral resection of the bladder tumor and two undergoing active surveillance. The median follow-up was 22 months (IQR, 15-26). In the intention-to-treat population, although the protocol-defined ypT0N0 rate was 9.1% (95% CI, 2.5 to 21.7), the overall ypT0N0-x rate was 29.5% (95% CI, 16.7 to 45.2), with an enrichment of ypT0 responses in nonluminal subtypes (46% v 14% of luminal). The 24-month event-free survival (EFS) rate was 71.4% (95% CI, 58 to 87.8), with longer EFS for participants with lower TOP1-expressing tumors. CONCLUSION: Neoadjuvant SG, at the reduced dose of 7.5 mg/kg, was active with a manageable safety profile, corroborating TROP2 as a suitable target for MIBC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Necchi A, de Jong JJ, Maiorano BA, et al. Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial. J Clin Oncol. 2026. PMID: 42218654. doi:10.1200/JCO-26-00142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。